TGIF HCV Weekely Rewind- Part 3: So You Think You’re a Hepatitis C Expert

Hello folks,

HCV Rewind is a look back at this weeks headlines, including today's news with updates as the day progresses.

Back in July Clinical Care Options released part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. In October CCO release part two of the series which included case scenarios from 11 leading international experts on hepatitis C, and today part three was released!

*Free registration is required

ClinicalQuiz™: So You Think You’re a Hepatitis C Expert, Educational Material, Part 3

Introduction
Hepatitis C is a rapidly evolving field with 2 newly available medications, recently updated treatment guidelines, and several investigational therapies in late stages of development. New therapies available for the treatment of patients infected with genotype 1 hepatitis C virus (HCV) have unique features that have changed the way clinicians treat the disease. At the same time, management of non–genotype 1 HCV has evolved as new data have highlighted strategies for optimizing treatment in these patients.

To help clinicians better apply current treatment guidelines and best management practices for hepatitis C, Raymond T. Chung, MD, and Jordan J. Feld, MD, MPH, together with 8 world-renowned hepatology experts, developed the educational program, “ClinicalQuiz™: So You Think You’re a Hepatitis C Expert,” an online and mobile game application designed to test knowledge and competence in treating hepatitis C.

Learning Objectives
Upon completion of this activity, participants should be able to:
Identify best practices for the treatment of hepatitis C with approved agents including boceprevir, telaprevir, peginterferon, and ribavirin
Assess and monitor the individualized care of patients receiving HCV therapy to address adverse events, adherence, and other issues
Assess and identify potential drug–drug interactions prior to the initiation of HCV protease inhibitor–based therapy

Topics covered include:
Pretreatment Management
Using Response-Guided Therapy With HCV Protease Inhibitors
Managing Adverse Events During Protease Inhibitor–Based HCV Therapy
Management of Drug-Drug Interactions During HCV Protease Inhibitor Therapy
Management of Special Populations and Non-Genotype 1 HCV

 
This Weeks Rewind
 
Awareness
An article written by Ann Mills over at " Triple Therapy For Hepatitis C"  looked at the role physicians play in testing high risk individuals for HCV. She urges clinicians to talk about hepatitis C with their patients, here is the article.

Social Media and Hepatitis C
Our favorite HCV Advocate Lucinda Porter, RN wrote an enlightening piece on her love hate relationship with social media, she questions everything she writes taking her responsibility to the HCV community to heart - one of the many reasons she is cherished and highly respected. The article "Hepatitis C and Social Media" is simply enchanting. As a side note this blog added a few links to online HCV support and toll free helplines, here.

Research
The debate rather to treat HCV or wait is ongoing, in the journal "Liver International" factors which affect the decision to treat now or delay therapy are discussed. You can view the article here: Patients with HCV and F1 and F2 fibrosis: treat now or wait? For additional updates on the topic click here

This week Liver International published a series of full text articles on the management of viral hepatitis which included genotypes 1-4, side effects of therapy, new agents in development, interferon free therapies and more. Check out all the updates: Special Issue: Proceedings of the 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis February 2013

Updates Telaprevir
Telaprevir - Analysis of geno 2 and 3 hepatitis C virus variants demonstrates a consistent resistance profile across genotypes

HCV drugs - A review of 2012 and a peek at 2013
Includes data on both Telaprevir and Boceprevir, with updates on a few promising therapies in development. *Updated Jan 6th

Sofosbuvir (GS-7977)
If you missed Gilead's update on their all-oral therapy with sofosbuvir (GS-7977), GS-5885 and ribavirin view all updates including investment commentary on the website, here.

Website
This weeks HCV news and clinical data on Fibrosis, Cirrhosis ,Transplant and Liver Cancer .

NATAP is the go to site for key HCV data, this weeks updates can be found here.

News This Week
CDC: Rare Blood Disorder Found in Intravenous Drug Users
Investigators discover new gene that affects clearance of hepatitis C virus

Big Pharma - This Week
Idenix Says FDA Needs More Time to Review Hold on Hepatitis C Drug
Investment Commentary Hepatitis C Market-Sofosbuvir's (GS-7977) Potential
Inovio to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
Hepatitis C: Vertex's strategy in hepatitis C is to develop new all-oral treatment regimens
Hepatitis C - Achillion Reports Interim Results on ACH-3102

Big Pharma - Todays Updates:
Gilead Criticized Over Price Hikes For AIDS Drugs
Idenix Pharmaceuticals CEO Presents at 31st Annual JPMorgan Healthcare Conference (Transcript)

Todays Updates:
HBV-infected patients died most often of hepatitis B-related issues
Non-invasive diagnosis of small hepatocellular carcinoma
London: Rise of sexually transmitted infections on gay scene linked to crystal meth

0 comments:

Post a Comment